IRIS
AMATI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 399
EU - Europa 284
AS - Asia 191
AF - Africa 6
OC - Oceania 4
SA - Sud America 4
Totale 888
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 394
CN - Cina 106
FI - Finlandia 85
IE - Irlanda 61
SG - Singapore 53
IT - Italia 45
DE - Germania 31
SE - Svezia 26
RU - Federazione Russa 19
IN - India 18
GB - Regno Unito 12
JP - Giappone 6
CA - Canada 5
HK - Hong Kong 5
AU - Australia 4
NG - Nigeria 4
KE - Kenya 2
NL - Olanda 2
PE - Perù 2
AR - Argentina 1
AT - Austria 1
BR - Brasile 1
FR - Francia 1
KR - Corea 1
PH - Filippine 1
TR - Turchia 1
UA - Ucraina 1
Totale 888
Salva come PNG Salva come JPEG
Città #
Boardman 107
Shanghai 97
Helsinki 85
New York 72
Dublin 61
Ashburn 53
Singapore 40
Los Angeles 25
Moscow 19
Pune 16
Chandler 14
Santa Clara 7
Shijiazhuang 7
Falkenstein 6
Naples 6
Casal di Principe 5
Milan 5
Wanchai 5
Benin City 4
Southwark 4
Cagliari 3
Dolianova 3
Guildford 3
London 3
Montecassiano 3
Phoenix 3
Asagayakita 2
Berlin 2
Daiba 2
Etobicoke 2
Frankfurt am Main 2
Kentville 2
Lawrence 2
Lima 2
Melbourne 2
Nairobi 2
Princeton 2
Ragusa 2
Sankt Augustin 2
Sydney 2
Verona 2
Amsterdam 1
Ankara 1
Camden 1
Castellammare di Stabia 1
Clifton 1
Concepción del Uruguay 1
Council Bluffs 1
Hangzhou 1
Heeten 1
Matsuyama 1
Mumbai 1
Paris 1
Qingdao 1
Suncheon-si 1
São Paulo 1
Tandag 1
Taunton 1
Winnipeg 1
Yoshizuka 1
Totale 705
Salva come PNG Salva come JPEG
Nome #
Diagnosis and management of patients with alpha 1-antitrypsin deficiency: an Italian perspective 54
COVID-19 in Immunocompromised Patients: A Systematic Review 43
Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases 34
Community-acquired pneumonia 33
An extensive bundle of tests is needed to detect treatable causes of bronchiectasis (Bx) 26
COVID-19 in lung transplant recipients: A case series from Milan, Italy 24
How to Identify Causes and Predisposing Factors in Bronchiectasis 24
Cardiovascular Complications in Community-Acquired Pneumonia 23
Respiratory failure in COVID-19: a patient's perspective and clinical cases 23
Post-COVID-19 sequelae 22
Cardiovascular side-effects of common antibiotics 21
COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia 21
Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia 20
Comparison of different conditions for DNA extraction in sputum - a pilot study 19
COVID-19 multidisciplinary high dependency unit: the Milan model 19
Alpha1-Antitrypsin Inherited Variants in Patients With Bronchiectasis 19
Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For 19
Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients 18
What is the best technique to extract bacterial DNA from sputum? 18
Antibiotics for lung disease and cancer 18
Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes 17
Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis 17
Genetic and Serum Screening for Alpha-1-Antitrypsin Deficiency in Adult Patients with Cystic Fibrosis: A Single-Center Experience 17
Hepatic and pulmonary involvement in a patient with PR3-ANCA vasculitis following SARS-CoV-2 vaccination: a case report 15
Treatable traits in interstitial lung diseases: a call to action 14
Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia 14
Neutrophil elastase in bronchiectasis 14
Protease-Antiprotease Imbalance in Bronchiectasis 14
Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia 14
Site of care and multidisciplinary approach 14
Diagnosis and Initial Investigation of Bronchiectasis 14
Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series 14
When and how ruling out cystic fibrosis in adult patients with bronchiectasis 13
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review 13
The biology of pulmonary exacerbations in bronchiectasis 13
Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review 12
Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia 12
Phenotyping in bronchiectasis: are we moving toward a personalized medicine? 12
Risk factors and guideline adherence of empiric antibiotic use in community-acquired pneumonia 11
Pro-resolving and pro-inflammatory fatty acid-derived mediators in sputum of stable state bronchiectasis patients 11
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity 11
Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study 10
Respiratory viruses in stable bronchiectasis: A multicenter evaluation in Northern Italy 10
Lung Recruitability of COVID-19 Pneumonia in Patients Undergoing Helmet CPAP 10
Prognostic parameters of in-hospital mortality in COVID-19 patients-An Italian experience 10
Dysregulation of the microbial ‘gut-lung’ axis in bronchiectasis 10
Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review 10
Emerging Resistance of Gram Negative Pathogens in Community-Acquired Pneumonia 10
Predictors of Helmet CPAP Failure in COVID-19 Pneumonia: A Prospective, Multicenter, and Observational Cohort Study 10
Switching to nebulised short acting bronchodilators does not increase the risk of arrhythmia in patients hospitalized with a COPD exacerbation 9
T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis 9
Glucocorticoid Therapy in COVID-19 8
Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients 8
Microbial Inflammatory Networks in Bronchiectasis Exacerbators With Pseudomonas aeruginosa 8
One Size Does Not Fit All: Moving Towards a Personalized Approach for Steroids in COVID-19 8
Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis 7
Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis 7
Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis 7
Walking the path of treatable traits in interstitial lung diseases 6
Response to: are there over 200 distinct types of interstitial lung diseases? 6
Treatable Traits in Systemic Sclerosis 3
First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases 3
Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis 3
Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review 2
Totale 958
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.582
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.582
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202211 0 0 0 0 0 0 0 0 2 3 4 2
2022/2023225 4 3 3 5 6 0 63 8 32 63 27 11
2023/2024715 53 64 122 67 32 107 68 31 9 45 50 67
2024/20257 7 0 0 0 0 0 0 0 0 0 0 0
Totale 958